Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Artículo en Inglés | MEDLINE | ID: mdl-33649164

RESUMEN

OBJECTIVE: B cells have emerged as a therapeutic target for MS. Anti-CD20 antibodies, which deplete B cells, are effective therapies for MS. However, atacicept (TACI-Fc), which blocks BAFF and APRIL and reduces B cells, unexpectedly exacerbates MS. We tested the hypothesis that B cell maturation antigen (BCMA), a receptor for BAFF and APRIL, plays a role in the paradoxical effects of anti-CD20 antibody and TACI-Fc using experimental autoimmune encephalomyelitis (EAE). METHODS: EAE was induced in wild-type (BCMA+/+) and BCMA-deficient (BCMA-/-) mice with an immunization of rodent myelin oligodendrocyte glycoprotein (MOG)35-55 peptide. Treatment with anti-CD20 antibody, TACI-Fc, and isotype controls was administered by intraperitoneal injections. CNS infiltration was evaluated by histology; immune cell phenotypes were evaluated by flow cytometry; MOG-specific antibodies were determined by ELISA. Mixed bone marrow chimeras and cell culture assays were used to identify the specific subsets of immune cells affected by BCMA deficiency. RESULTS: First, we found that BCMA-/- mice had more severe EAE compared with BCMA+/+ mice and the increased disease was associated with elevated anti-MOG B-cell responses. Second, we found that anti-CD20 therapy attenuated EAE in BCMA-/- mice but not in BCMA+/+ mice. Third, TACI-Fc attenuated EAE in BCMA+/+ mice but not in BCMA-/- mice. Mixed bone marrow chimeric and cell culture experiments demonstrated that BCMA deficiency elevates inflammatory B-cell responses but inhibits inflammatory responses in macrophages. CONCLUSIONS: BCMA has multifaceted roles during inflammation that affects therapeutic efficacies of anti-CD20 and TACI-Fc in EAE. Our results from BCMA-deficient mice provide insights into the failure of atacicept in MS.


Asunto(s)
Antígeno de Maduración de Linfocitos B/deficiencia , Encefalomielitis Autoinmune Experimental/tratamiento farmacológico , Encefalomielitis Autoinmune Experimental/inmunología , Proteínas Recombinantes de Fusión/farmacología , Animales , Anticuerpos , Autoinmunidad , Factor Activador de Células B/metabolismo , Linfocitos B/inmunología , Encefalomielitis Autoinmune Experimental/inducido químicamente , Humanos , Ratones , Ratones Endogámicos C57BL , Modelos Animales , Esclerosis Múltiple/tratamiento farmacológico , Esclerosis Múltiple/inmunología , Glicoproteína Mielina-Oligodendrócito/farmacología , Miembro 13 de la Superfamilia de Ligandos de Factores de Necrosis Tumoral/metabolismo
2.
J Immunol ; 186(11): 6136-47, 2011 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-21536804

RESUMEN

Systemic lupus erythematosus and its preclinical lupus-prone mouse models are autoimmune disorders involving the production of pathogenic autoantibodies. Genetic predisposition to systemic lupus erythematosus results in B cell hyperactivity, survival of self-reactive B cells, and differentiation to autoantibody-secreting plasma cells (PCs). These corrupt B cell responses are, in part, controlled by excess levels of the cytokine BAFF that normally maintains B cell homeostasis and self-tolerance through limited production. B cell maturation Ag (BCMA) is a receptor for BAFF that, under nonautoimmune conditions, is important for sustaining enduring Ab protection by mediating survival of long-lived PCs but is not required for B cell maturation and homeostasis. Through analysis of two different lupus-prone mouse models deficient in BCMA, we identify BCMA as an important factor in regulating peripheral B cell expansion, differentiation, and survival. We demonstrate that a BCMA deficiency combined with the lpr mutation or the murine lupus susceptibility locus Nba2 causes dramatic B cell and PC lymphoproliferation, accelerated autoantibody production, and early lethality. This study unexpectedly reveals that BCMA works to control B cell homeostasis and self-tolerance in systemic autoimmunity.


Asunto(s)
Autoinmunidad/inmunología , Antígeno de Maduración de Linfocitos B/deficiencia , Lupus Eritematoso Sistémico/inmunología , Trastornos Linfoproliferativos/inmunología , Animales , Factor Activador de Células B/inmunología , Factor Activador de Células B/metabolismo , Antígeno de Maduración de Linfocitos B/genética , Linfocitos B/inmunología , Linfocitos B/metabolismo , Diferenciación Celular/inmunología , Femenino , Citometría de Flujo , Immunoblotting , Estimación de Kaplan-Meier , Lupus Eritematoso Sistémico/genética , Lupus Eritematoso Sistémico/metabolismo , Ganglios Linfáticos/inmunología , Ganglios Linfáticos/metabolismo , Ganglios Linfáticos/patología , Activación de Linfocitos/inmunología , Trastornos Linfoproliferativos/genética , Trastornos Linfoproliferativos/metabolismo , Masculino , Ratones , Ratones de la Cepa 129 , Ratones Endogámicos C57BL , Ratones Noqueados , Mutación , Células Plasmáticas/inmunología , Células Plasmáticas/metabolismo , Autotolerancia/inmunología , Bazo/inmunología , Bazo/metabolismo , Bazo/patología
3.
Semin Immunol ; 18(5): 284-9, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16931039

RESUMEN

BAFF is a key factor controlling B cell survival and maturation and its over-expression promotes B cell-mediated autoimmune disorders and participates in the progression of B cell lymphomas. Yet, BAFF and a related ligand APRIL are expressed by T lymphocytes and modulate their functions. BAFF and APRIL promote T cell activation and survival. BAFF over-expression in transgenic (Tg) mice enhances T helper 1 (Thl)-driven delayed-type hypersensitivity (DTH), but inhibits T helper 2 (Th2) cell-mediated allergic airway inflammation in mice. Some of these effects are also dependent on BAFF-induced modification of the B cell compartment. Therefore, direct BAFF/APRIL signalling in T cells and/or T cell modulation in response to a BAFF-modified B cell compartment may play an important role in inflammation and immunomodulation.


Asunto(s)
Factor Activador de Células B/inmunología , Receptor del Factor Activador de Células B/inmunología , Antígeno de Maduración de Linfocitos B/inmunología , Subgrupos de Linfocitos T/inmunología , Proteína Activadora Transmembrana y Interactiva del CAML/inmunología , Miembro 13 de la Superfamilia de Ligandos de Factores de Necrosis Tumoral/inmunología , Animales , Autoinmunidad/inmunología , Factor Activador de Células B/deficiencia , Factor Activador de Células B/genética , Receptor del Factor Activador de Células B/deficiencia , Receptor del Factor Activador de Células B/genética , Antígeno de Maduración de Linfocitos B/deficiencia , Antígeno de Maduración de Linfocitos B/genética , Diferenciación Celular , Proteínas de Homeodominio/genética , Proteínas de Homeodominio/fisiología , Humanos , Inflamación/inmunología , Activación de Linfocitos , Linfocinas/biosíntesis , Ratones , Ratones Noqueados , Ratones Transgénicos , Subgrupos de Linfocitos T/metabolismo , Proteína Activadora Transmembrana y Interactiva del CAML/deficiencia , Proteína Activadora Transmembrana y Interactiva del CAML/genética , Miembro 13 de la Superfamilia de Ligandos de Factores de Necrosis Tumoral/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA